Cladribine for highly active relapsing multiple sclerosis.
- Published in:
- Prescriber, 2018, v. 29, n. 2, p. 37, doi. 10.1002/psb.1652
- By:
- Publication type:
- Article
Works matching IS 09596682 AND DT 2018 AND VI 29 AND IP 2
Results: 8
1
2
New ways of dealing with new psychoactive substances.
- Published in:
- Prescriber, 2018, v. 29, n. 2, p. 33, doi. 10.1002/psb.1651
- By:
- Publication type:
- Article
3
Prescribing and monitoring non‐biological DMARDs.
- Published in:
- Prescriber, 2018, v. 29, n. 2, p. 29, doi. 10.1002/psb.1650
- By:
- Publication type:
- Article
4
Diagnosis and management of Parkinson's disease in adults.
- Published in:
- Prescriber, 2018, v. 29, n. 2, p. 25, doi. 10.1002/psb.1649
- By:
- Publication type:
- Article
5
Can pharmacists promote self‐care using digital technology?
- Published in:
- Prescriber, 2018, v. 29, n. 2, p. 21, doi. 10.1002/psb.1648
- By:
- Publication type:
- Article
6
Accounting for cardiovascular risk when prescribing NSAIDs.
- Published in:
- Prescriber, 2018, v. 29, n. 2, p. 15, doi. 10.1002/psb.1647
- By:
- Publication type:
- Article
7
Management of genital herpes: a guide for GPs.
- Published in:
- Prescriber, 2018, v. 29, n. 2, p. 11, doi. 10.1002/psb.1646
- By:
- Publication type:
- Article
8
Designer drugs – outside the law but still a problem.
- Published in:
- Prescriber, 2018, v. 29, n. 2, p. 4, doi. 10.1002/psb.1645
- By:
- Publication type:
- Article